OCT 05, 2016 10:30 AM PDT

Immunotherapy of Cancer Using Genetically-Enhanced T Cells

Speaker
  • Assistant Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania, Associate Director, Toxicology Laboratory, University of Pennsylvania Perelman Scho
    Biography
      Dr. Milone received his M.D. and Ph.D. in experimental pathology in 1999 from Rutgers-New Jersey Medical School (formerly the University of Medicine and Dentistry of New Jersey). After an Internship in Internal Medicine at the Hospital of the University of Pennsylvania, he completed post-graduate medical training in Clinical Pathology, Transfusion Medicine and Laboratory Toxicology. Following clinical training, Dr. Milone pursued post-doctoral research training in cancer immunology and adoptive immunotherapy with Dr. Carl June at the University of Pennsylvania where he performed basic research to develop CTL019, a genetically modified T cell therapy for B-cell leukemia and lymphoma that has been licensed by Novartis and undergoing early phase clinical testing. He is currently an Assistant Professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine. At present, Dr. Milone's laboratory is focused on T cell biology and the development of new techniques for culturing and genetically modifying T lymphocytes for adoptive immunotherapy of cancer.

    Abstract

    The immune system possesses significant cytotoxic potential. Stimulating natural immunity through vaccination has shown promising effects in some cancers; however, a number of barriers limit the efficacy of the natural immune system including tolerance to self-antigens and immunodeficiency associated with cancer and associated chemotherapy.  Adoptive immunotherapy using T-cells that are genetically modified to express an artificial receptor that combines the antigen specificity of an antibody with the signal transduction machinery of the T-cell receptor in a single chimeric antigen receptor (CAR) hold significant promise for overcoming many of the barriers to anti-cancer immunity.  This talk will describe the clinical applications of CARs that target CD19, a molecule expressed by normal B-cells and cells in a range of B-cell malignancies including acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) as well as a CARs targeting BCMA for multiple myeloma and mesothelin for solid malignancies. Toxicity related to this cell therapy that includes a cytokine release syndrome and long term B-cell aplasia will also be discussed.
     


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    MAR 18, 2021 8:00 AM PDT
    C.E. CREDITS
    MAR 18, 2021 8:00 AM PDT
    DATE: March 18, 2021 TIME: 8:00am PDT Sequencing of bulk cells, single cells, and nuclei is opening doors in the understanding of complex biological processes....
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    OCT 05, 2016 10:30 AM PDT

    Immunotherapy of Cancer Using Genetically-Enhanced T Cells


    Specialty

    Cancer Research

    Immunology

    Biotechnology

    Dna

    Cell Biology

    Clinical Diagnostics

    T-Cells

    Clinical Research

    Cancer Diagnostics

    Flow Cytometry

    Research

    Cell Culture

    Genetics

    Antibodies

    Gene Expression

    Geography

    North America40%

    Asia40%

    Europe20%

    Registration Source

    Website Visitors100%

    Job Title

    Student60%

    Clinical Laboratory Scientist20%

    Educator/Faculty20%

    Organization

    Academic Institution80%

    Hospital20%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more